<?xml version='1.0' encoding='utf-8'?>
<document id="22251436"><sentence text="Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial."><entity charOffset="0-9" id="DDI-PubMed.22251436.s1.e0" text="Maraviroc" /></sentence><sentence text="The purpose of this study was to determine whether maraviroc, a human CC chemokine receptor 5 (CCR5) antagonist, is safe and effective in the treatment of active rheumatoid arthritis (RA) in patients on background methotrexate (MTX)"><entity charOffset="51-60" id="DDI-PubMed.22251436.s2.e0" text="maraviroc" /><entity charOffset="214-226" id="DDI-PubMed.22251436.s2.e1" text="methotrexate" /><entity charOffset="228-231" id="DDI-PubMed.22251436.s2.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.22251436.s2.e0" e2="DDI-PubMed.22251436.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22251436.s2.e0" e2="DDI-PubMed.22251436.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22251436.s2.e0" e2="DDI-PubMed.22251436.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22251436.s2.e1" e2="DDI-PubMed.22251436.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22251436.s2.e1" e2="DDI-PubMed.22251436.s2.e2" /></sentence><sentence text="" /><sentence text="This phase IIa study comprised two distinct components: an open-label safety study of the pharmacokinetics (PK) of MTX in the presence of maraviroc, and a randomized, double-blind, placebo-controlled, proof-of-concept (POC) component"><entity charOffset="115-118" id="DDI-PubMed.22251436.s4.e0" text="MTX" /><entity charOffset="138-147" id="DDI-PubMed.22251436.s4.e1" text="maraviroc" /><pair ddi="false" e1="DDI-PubMed.22251436.s4.e0" e2="DDI-PubMed.22251436.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22251436.s4.e0" e2="DDI-PubMed.22251436.s4.e1" /></sentence><sentence text=" In the PK component, patients were randomized 1:1 to receive maraviroc 150 or 300 mg twice daily (BID) for four weeks"><entity charOffset="62-71" id="DDI-PubMed.22251436.s5.e0" text="maraviroc" /></sentence><sentence text=" In the POC component, patients were randomized 2:1 to receive maraviroc 300 mg BID or placebo for 12 weeks"><entity charOffset="63-72" id="DDI-PubMed.22251436.s6.e0" text="maraviroc" /></sentence><sentence text=" Patients were not eligible for inclusion in both components" /><sentence text="" /><sentence text="Sixteen patients were treated in the safety/PK component" /><sentence text=" Maraviroc was well tolerated and there was no evidence of drug-drug interaction with MTX"><entity charOffset="1-10" id="DDI-PubMed.22251436.s10.e0" text="Maraviroc" /><entity charOffset="86-94" id="DDI-PubMed.22251436.s10.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.22251436.s10.e0" e2="DDI-PubMed.22251436.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22251436.s10.e0" e2="DDI-PubMed.22251436.s10.e1" /></sentence><sentence text=" One hundred ten patients were treated in the POC component" /><sentence text=" The study was terminated after the planned interim futility analysis due to lack of efficacy, at which time 59 patients (38 maraviroc; 21 placebo) had completed their week 12 visit" /><sentence text=" There was no significant difference in the number of ACR20 responders between the maraviroc (23"><entity charOffset="83-92" id="DDI-PubMed.22251436.s13.e0" text="maraviroc" /></sentence><sentence text="7%) and placebo (23" /><sentence text="8%) groups (treatment difference -0" /><sentence text="13%; 90% CI -20" /><sentence text="45, 17" /><sentence text="70; P = 0" /><sentence text="504)" /><sentence text=" The most common all-causality treatment-emergent adverse events in the maraviroc group were constipation (7"><entity charOffset="72-81" id="DDI-PubMed.22251436.s20.e0" text="maraviroc" /></sentence><sentence text="8%), nausea (5" /><sentence text="2%), and fatigue (3" /><sentence text="9%)" /><sentence text="" /><sentence text="Maraviroc was generally well tolerated over 12 weeks; however, selective antagonism of CCR5 with maraviroc 300 mg BID failed to improve signs and symptoms in patients with active RA on background MTX"><entity charOffset="0-9" id="DDI-PubMed.22251436.s25.e0" text="Maraviroc" /><entity charOffset="97-106" id="DDI-PubMed.22251436.s25.e1" text="maraviroc" /><entity charOffset="196-204" id="DDI-PubMed.22251436.s25.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.22251436.s25.e0" e2="DDI-PubMed.22251436.s25.e0" /><pair ddi="false" e1="DDI-PubMed.22251436.s25.e0" e2="DDI-PubMed.22251436.s25.e1" /><pair ddi="false" e1="DDI-PubMed.22251436.s25.e0" e2="DDI-PubMed.22251436.s25.e2" /><pair ddi="false" e1="DDI-PubMed.22251436.s25.e1" e2="DDI-PubMed.22251436.s25.e1" /><pair ddi="false" e1="DDI-PubMed.22251436.s25.e1" e2="DDI-PubMed.22251436.s25.e2" /></sentence><sentence text="" /><sentence text="ClinicalTrials" /><sentence text="gov:  NCT00427934" /><sentence text="" /></document>